Critical Review: Repligen Corporation (RGEN) and Aimmune Therapeutics (AIMT)
Repligen Corporation (NASDAQ: RGEN) and Aimmune Therapeutics (NASDAQ:AIMT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.
Valuation & Earnings
This table compares Repligen Corporation and Aimmune Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Repligen Corporation||$113.32 million||14.40||$29.54 million||$0.51||85.63|
|Aimmune Therapeutics||N/A||N/A||-$106.22 million||($2.25)||-9.55|
Repligen Corporation has higher revenue and earnings than Aimmune Therapeutics. Aimmune Therapeutics is trading at a lower price-to-earnings ratio than Repligen Corporation, indicating that it is currently the more affordable of the two stocks.
This table compares Repligen Corporation and Aimmune Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility & Risk
Repligen Corporation has a beta of 1.3, indicating that its stock price is 30% more volatile than the S&P 500. Comparatively, Aimmune Therapeutics has a beta of -1.12, indicating that its stock price is 212% less volatile than the S&P 500.
This is a summary of recent recommendations and price targets for Repligen Corporation and Aimmune Therapeutics, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Repligen Corporation presently has a consensus price target of $41.00, indicating a potential downside of 6.11%. Aimmune Therapeutics has a consensus price target of $36.67, indicating a potential upside of 70.62%. Given Aimmune Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Aimmune Therapeutics is more favorable than Repligen Corporation.
Institutional and Insider Ownership
97.9% of Repligen Corporation shares are held by institutional investors. Comparatively, 72.9% of Aimmune Therapeutics shares are held by institutional investors. 1.5% of Repligen Corporation shares are held by insiders. Comparatively, 24.6% of Aimmune Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Repligen Corporation beats Aimmune Therapeutics on 8 of the 11 factors compared between the two stocks.
Repligen Corporation Company Profile
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products. It provides Protein A ligands, a component of Protein A chromatography resins (media) used in the purification of virtually all monoclonal antibody (mAb)-based drugs on the market or in development. Its chromatography portfolio includes various products used in the downstream purification and quality control of biological drugs. Its OPUS pre-packed chromatography columns (PPCs) are used in the purification of clinical-stage biologics. Its filtration products include XCell Alternating Tangential Flow (ATF) Systems and Sius tangential flow filtration (TFF) cassettes. Sius TFF cassettes are used to concentrate clinical and commercial-stage biologic drugs.
Aimmune Therapeutics Company Profile
Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services. The Company’s lead CODIT product candidate, AR101, is an investigational biologic for the treatment of patients with peanut allergy. The Company has initiated Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE), its Phase III registration trial of AR101. The Company is in the process of evaluating additional delivery forms for AR101 for the maintenance phase.
Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.